| Companies sponsors |
Swedish Orphan Biovitrum (loncastuximab tesirine) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Blood Cancer UK |
| |
Lymphoma Action |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Associated public health groups |
None |
| Comparator companies |
Baxter Healthcare (ifosfamide) |
| |
Bristol-Myers Squibb (lenalidomide) (confidentialiy agreement signed, participating) |
| |
Kite pharma (axicabtagene ciloleucel) (confidentiality agreement signed, participating) |
| |
Roche (rituximab, polatuzumab vedotin) (confidentiality agreement signed, participating) |
| |
Accord Healthcare (bendamustine, cisplatin, cytarabine, gemcitabine, carboplatin, etoposide, epirubicin, lenalidomide, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Baxter Healthcare (ifosfamide) (confidentiality agreeement not signed, not participating) |
| |
Celltrion (rituximab) (confidentiality agreement not signed, not participating) |
| |
Consilient Health (bendamustine, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Dr Reddy’s Laboratories (bendamustine) (confidentiality agreement not signed, not participating) |
| |
Fresenius Kabi (gemcitabine, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Hospira UK (cisplatin, cytarabine, gemcitabine, carboplatin) (confidentiality agreement not signed, not participating) |
| |
Incyte biosciences (tafasitamab) (confidentiality agreement not signed, not participating) |
| |
Medac (etoposide, epirubicin, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Napp Pharmaceuticals (rituximab) (confidentiality agreement not signed, not participating) |
| |
Neon Healthcare (etoposide) (confidentiality agreement not signed, not participating) |
| |
Pfizer (epirubicin, rituximab, cytarabine, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Sandoz (rituximab, lenalidomide, cisplatin) (confidentiality agreement not signed, not participating) |
| |
Seacross Pharmaceuticals (epirubicin, bendamustine, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Servier Laboratories (pixantrone) (confidentiality agreement not signed, not participating) |
| |
Stragen UK (lenalidomide) (confidentiality agreement not signed, not participating) |
| |
Sun Pharmaceuticals (gemcitabine, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Teva UK (lenalidomide) (confidentiality agreement not signed, not participating) |
| |
Thornton and Ross (lenalidomide) (confidentiality agreement not signed, not participating) |
| |
Torrent pharma (lenalidomide) (confidentiality agreement not signed, not participating) |
| |
Zentiva (bendamustine, lenalidomide) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |